331. 特発性多中心性キャッスルマン病 Idiopathic multicentric castleman disease Clinical trials / Disease details

臨床試験数 : 33 / 薬物数 : 41 - (DrugBank : 21) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 123

3 trials found

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCT2071190029	25/05/2020	09/10/2019	Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimusfor tocilizumab-resis ...	Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimusfor tocilizumab-resis ...	idiopathic multicentric Castleman's disease Castleman's disease	Treatment: Sirolimus 2 mg po once/day. Control: Placebo given orally once daily	Kawakami Atsushi	NULL	Complete	>= 18age old	Not applicable	Both	20	Phase 2	Japan
2	NCT03933904 (ClinicalTrials.gov)	September 25, 2019	29/4/2019	Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease	A Phase II, Single-arm Open-label Multi-center Study of Sirolimusin Previously Treated Idiopathic Mu ...	Castleman Disease;Castleman's Disease, Multicentric	Drug: Sirolimus	University of Pennsylvania	NULL	Recruiting	2 Years	80 Years	All	24	Phase 2	United States
3	NCT00092222 (ClinicalTrials.gov)	October 28, 2004	21/9/2004	Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Corr ...	Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's ...	Lymphoproliferative Disorder;HHV-8;Malignancy;HIV	Drug: Etoposide;Drug: Interferon-alpha;Drug: Rituximab;Drug: Zidovudine;Drug: Liposomal Doxorubicin; ...	National Cancer Institute (NCI)	NULL	Active, not recruiting	18 Years	N/A	All	75	Phase 2	United States

First Previous1Next Last